Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Iran leader bans import of U.S., UK COVID-19 vaccines, demands sanctions end

Fri, 08th Jan 2021 09:13

(Adds Twitter removes Khamenei tweet)

By Parisa Hafezi

DUBAI, Jan 8 (Reuters) - Iran's Supreme Leader on Friday
banned the government from importing COVID-19 vaccines from the
United States and Britain, labelling the Western powers
"untrustworthy", as the infection spreads in the Middle East’s
hardest-hit country.

In a live televised speech, Ayatollah Ali Khamenei raised
the prospect of the two Western countries, long-time adversaries
of the Islamic Republic, possibly seeking to spread the
infection to other countries.

He added however that Iran could obtain vaccines "from other
reliable places". He gave no details, but China and Russia are
both allies of Iran.

"Imports of U.S. and British vaccines into the country are
forbidden ... They're completely untrustworthy. It's not
unlikely they would want to contaminate other nations," said
Khamenei, the country's highest authority.

"Given our experience with France's HIV-tainted blood
supplies, French vaccines aren't trustworthy either," Khamenei
said, referring to the country's contaminated blood scandal of
the 1980s and 1990s.

Khamenei repeated the accusations in a tweet that was
removed by Twitter along with a message saying it violated the
platform's rules against misinformation.

Iran launched human trials of its first domestic COVID-19
vaccine candidate late last month, saying it could help Iran
defeat the pandemic despite U.S. sanctions that affect its
ability to import vaccines.

Tensions between Washington and Tehran have risen since
2018, when President Donald Trump abandoned a 2015 nuclear deal
and reimposed sanctions to pressure Iran into negotiating
stricter curbs on its nuclear program, ballistic missile
development and support for regional proxy forces.

In retaliation for U.S. sanctions, which were lifted under
the nuclear deal, Tehran has gradually violated the accord. U.S.
President-elect Joe Biden, who takes office on Jan. 20, has
pledged to rejoin the agreement if Tehran also returns to full
compliance.

Khamenei said Tehran was in no rush for the United States to
re-enter the deal, but that sanctions on the Islamic Republic
must be lifted immediately.

Iran's utmost authority, Khamenei ruled out any talks over
Tehran's missile programme and Iran's involvement in the Middle
East, as demanded by the United States and some other major
powers.

"Contrary to the U.S., Iran's involvement in the region
creates stability and is aimed at preventing instability ...
Iran’s involvement in the region is definite and will continue."

Shortly before Khamenei's speech, Iran's elite Revolutionary
Guards unveiled an underground missile base at an undisclosed
Gulf location.

The West sees Iran’s missiles both as a conventional
military threat to regional stability and a possible delivery
mechanism for nuclear weapons should Tehran develop them.

But Iran, which has one of the biggest missile programmes in
the Middle East, regards the programme as an important deterrent
and retaliatory force against the United States and other
adversaries - primarily Gulf Arabs - in the region in the event
of war.
(Reporting by Parisa Hafezi; Editing by Toby Chopra, Timothy
Heritage, William Maclean and Sonya Hepinstall)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.